MLchartDataset catalogue

Margenza

Term · Oncology and biomedicine · MLC-T-ONC-005134

A drug used with other drugs to treat adults with HER2-positive breast cancer that has spread to other parts of the body. It is used in patients who have already received at least two anti-HER2 treatments, including at least one for metastatic disease. It is also being studied in the treatment of other types of cancer. Margenza binds to a protein called HER2, which is found on some cancer cells. This may help the immune system kill cancer cells. Margenza is a type of monoclonal antibody. Also called margetuximab.

Table 1. Record
IdentifierMLC-T-ONC-005134
FieldOncology and biomedicine
Synonymsmargetuximab
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-005134",
  "term": "Margenza",
  "field": "Oncology and biomedicine",
  "definition": "A drug used with other drugs to treat adults with HER2-positive breast cancer that has spread to other parts of the body. It is used in patients who have already received at least two anti-HER2 treatments, including at least one for metastatic disease. It is also being studied in the treatment of other types of cancer. Margenza binds to a protein called HER2, which is found on some cancer cells. This may help the immune system kill cancer cells. Margenza is a type of monoclonal antibody. Also called margetuximab.",
  "synonyms": [
    "margetuximab"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/margenza/"
}

Record 10,633 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.